Multimedia
Videos
Sponsored Content
Please view the video to learn more about recommending new Alka-Seltzer Plus®-D Multi-Symptom Sinus and Cold Liquid Gels to patients who need multi-symptom relief for burdensome cold and sinus symptoms. No other behind-the-counter product relieves more cold and sinus symptoms.
Histamine and Antihistamines
Sara Anvari, MD, discusses the function of histamine in the immune response and treatment with antihistamines.
Ocular Allergy
Leonard Bielory, MD, reviews challenging cases of ocular allergy and discusses treatment options.
Atopic Dermatitis
Luz Fonacier, MD, talks about the diagnosis and management of atopic dermatitis.
Diabetes Management Can Reduce Employer Health Care Costs
Jonathan G. Marquess, PharmD, CDE, explains that employers can save a great deal on health care costs by helping their employees with diabetes effectively manage their condition.
Hydrocodone Combination Product Rescheduling: The Bigger Picture
Jeff Fudin, PharmD, FCCP, argues that the way to make hydrocodone combination products safer for patients is to provide more education for those who prescribe the medications and pharmacists who dispense them.
Why Should Hydrocodone Combination Products Be Categorized as CII Drugs?
Mary Lynn McPherson, PharmD, explains why hydrocodone combination products should no longer be categorized as Schedule III drugs.
Codeine and Rescheduling Hydrocodone Combination Products
Jeff Fudin, PharmD, FCCP, argues that categorizing hydrocodone combination products as Schedule II could lead to increased prescription of codeine, a much “sloppier” drug that could create problems for patients.
Rescheduling Hydrocodone Combination Products Will Lead to More Responsible Use
Mary Lynn McPherson, PharmD, argues that rescheduling hydrocodone combination products will lead to more responsible prescribing of the drugs and monitoring of their use.
Rescheduling Hydrocodone Combination Products: Lessons from New York State
Jeff Fudin, PharmD, FCCP, discusses the effect of rescheduling hydrocodone combination products as CII in New York State on prescription of other opioids, including oxycodone.
